CD19 and hematopoietic and lymphoid cell neoplasm: The adoptive transfer of gene-modified T-cells holds tremendous immunotherapeutic potential as exemplified by the curative responses now documented for some hematological cancer patients treated by chimeric antigen receptor (CAR)-T cells targeting the B-cell lineage antigen CD19.59